EUVIMEDEUVIMED entdecken
Crossref

Cannabinoid 2 Receptor Activation Protects against Diabetic Cardiomyopathy through Inhibition of AGE/RAGE-Induced Oxidative Stress, Fibrosis, and Inflammasome Activation

Hebaallah Mamdouh Hashiesh, Sheikh Azimullah, Mohamed Fizur Nagoor Meeran, Dhanya Saraswathiamma, Seenipandi Arunachalam, Niraj Kumar Jha, Bassem Sadek, Ernest Adeghate, Gautam Sethi, Alia Albawardi, Saeeda Al Marzooqi, Shreesh Ojha iD

The Journal of Pharmacology and Experimental Therapeutics · 2024

DOI: 10.1124/jpet.123.002037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024. Verfasst von Hebaallah Mamdouh Hashiesh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pharmacology and Therapeutics (H.M.H., Sh.A., M.F.N.M., Se.A., B.S., S.O.), Pathology (D.S., A.A., S.A.M.), and Anatomy (E.A.), Colleg…. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Fibrosis, Glycation End Products, Advanced, Inflammasomes. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 101 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxidative stress, fibrosis, and inflammasome activation from advanced glycation end product (AGE)-receptor of advanced glycation end product (RAGE) interaction contribute to diabetic cardiomyopathy (DCM) formation and progression. Our study revealed the impact of β-caryophyllene (BCP) on activating cannabinoid type 2 receptors (CB2Rs) against diabetic complication, mainly cardiomyopathy and investigated the underlying cell signaling pathways in mice. The murine model of DCM was developed by feeding a high-fat diet with streptozotocin injections. After the development of diabetes, the animals received a 12-week oral BCP treatment at a dose of 50 mg/kg/body weight. BCP treatment showed significant improvement in glucose tolerance and insulin resistance and enhanced serum insulin levels in diabetic animals. BCP treatment effectively reversed the heart remodeling and restored the phosphorylated troponin I and sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a expression. Ultrastructural examination showed reduced myocardial cell injury in DCM mice treated with BCP. The preserved myocytes were found to be associated with reduced expression of AGE/RAGE in DCM mice hearts. BCP treatment mitigated oxidative stress by inhibiting expression of NADPH oxidase 4 and activating phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/nuclear factor erythroid 2-related factor 2 (Nrf2) signaling. Also, BCP suppressed cardiac fibrosis and endothelial-to-mesenchymal transition in DCM mice by inhibiting transforming growth factor β (TGF-β)/suppressor of mothers against decapentaplegic (Smad) signaling. Further, BCP treatment suppressed nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome activation in DCM mice and alleviated cellular injury to the pancreatic tissues evidenced by significant elevation of the number of insulin-positive cells. To demonstrate a CB2R-dependent mechanism of BCP, another group of DCM mice were pretreated with AM630, a CB2R antagonist. AM630 was observed to abrogate the beneficial effects of BCP in DCM mice. Taken together, BCP demonstrated the potential to protect the myocardium and pancreas of DCM mice mediating CB2R-dependent mechanisms. SIGNIFICANCE STATEMENT: BCP, a CB2R agonist, shows protection against DCM. BCP attenuates oxidative stress, inflammation, and fibrosis in DCM via activating CB2Rs. BCP mediating CB2R activation favorably modulates AGE/RAGE, PI3K/AKT/Nrf2β and TGF-β/Smad and (NLRP3) inflammasome in diabetic cardiomyopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic CardiomyopathiesFibrosisGlycation End Products, AdvancedInflammasomesOxidative StressReceptor for Advanced Glycation End ProductsReceptor, Cannabinoid, CB2AnimalsMaleMiceMice, Inbred C57BLSignal Transduction

Substanzen

Glycation End Products, AdvancedInflammasomesReceptor for Advanced Glycation End ProductsReceptor, Cannabinoid, CB2

Autor:innen und Institutionen

  • Departments of Pharmacology and Therapeutics (H.M.H., Sh.A., M.F.N.M., Se.A., B.S., S.O.), Pathology (D.S., A.A., S.A.M.), and Anatomy (E.A.), College of Medicine and Health Sciences, and Zayed Bin Sultan Center for Hea…

ORCID-Profile: Shreesh Ojha

Zitieren

APA

Hashiesh, H. M., Azimullah, S., Nagoor Meeran, M. F., Saraswathiamma, D., Arunachalam, S., Jha, N. K., Sadek, B., Adeghate, E., Sethi, G., Albawardi, A., Al Marzooqi, S., & Ojha, S. (2024). Cannabinoid 2 Receptor Activation Protects against Diabetic Cardiomyopathy through Inhibition of AGE/RAGE-Induced Oxidative Stress, Fibrosis, and Inflammasome Activation. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.002037

Vancouver

Hashiesh HM, Azimullah S, Nagoor Meeran MF, Saraswathiamma D, Arunachalam S, Jha NK, et al. Cannabinoid 2 Receptor Activation Protects against Diabetic Cardiomyopathy through Inhibition of AGE/RAGE-Induced Oxidative Stress, Fibrosis, and Inflammasome Activation. The Journal of Pharmacology and Experimental Therapeutics. 2024. doi:10.1124/jpet.123.002037

BibTeX
@article{Hashiesh2024,
  author = {Hashiesh, Hebaallah Mamdouh and Azimullah, Sheikh and Nagoor Meeran, Mohamed Fizur and Saraswathiamma, Dhanya and Arunachalam, Seenipandi and Jha, Niraj Kumar and Sadek, Bassem and Adeghate, Ernest and Sethi, Gautam and Albawardi, Alia and Al Marzooqi, Saeeda and Ojha, Shreesh},
  title = {Cannabinoid 2 Receptor Activation Protects against Diabetic Cardiomyopathy through Inhibition of AGE/RAGE-Induced Oxidative Stress, Fibrosis, and Inflammasome Activation},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  doi = {10.1124/jpet.123.002037}
}
Kostenlos starten →